Autolus Therapeutics to host Investor Conference Call to discuss AUTO3 data presented at ESMO and to participate in Banking conferences through September
LONDON, Sept. 08, 2020(GLOBE NEWSWIRE) Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will host an investor conference call to discuss AUTO3 data presented at the
9 September 2020– The company will participate in an analyst moderated group meeting at the Wells Fargo Virtual Healthcare Conferenceat 9.20 am EDT, 2.20 pm BSTand will also host virtual one-on-one meetings. A live audio webcast of the fireside chat will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be available for a period of 30 days after the conference.
15 September 2020– The company will present at the H.C. Wainwright& Co 22nd Annual Global Investment Conferenceat 10.30 am EDT, 3.30 pm BSTand will also host virtual one-on-one meetings. A live audio webcast of the presentation will be available on the investor relations section of the Company’s website at Autolus. An archived replay will be available for a period of 30 days after the conference.
17 September 2020– The company will present at the Cantor Fitzgerald Virtual Global Healthcare Conferenceat 4.00 pm EDT, 9.00 pm BSTand will also host virtual one-on-one meetings.
18 September 2020– Dr. Christian Itin, chairman and chief executive officer, along with the AUTO3 clinical team, will host an investor call and webcast at 8.00 am EDT, 1.00 pm BSTto discuss a presentation related to its AUTO3 program, the company’s CAR T cell therapy being investigated in the Alexander study, a Phase 1/2 study in relapsed/ refractory diffuse large B cell lymphoma (DLBCL), during the ESMO conference. To listen to the webcast and view the accompanying slide presentation, please go to Autolus.
The call may also be accessed by dialing (866) 652-5200 for
U.S.and Canadacallers or (412) 317-6060 for International callers. Please ask to be joined into the Autolus Therapeuticscall. An archived replay will be available for a period of 12 months after the call. 22 September 2020– The company will participate in a Q&A at the virtual JP Morgan CEO Series Investor Call at 11.00 am EDT, 4.00 pm BST.
Vice President, Investor Relations and Corporate Communications
+44 (0) 7587 372 619
+44 (0) 7818 430877
Source: Autolus Therapeutics plc